Evidence map›Paper›PMID 36170362›Full record

ArticleScience advances2022

Microfluidic affinity selection of active SARS-CoV-2 virus particles.

Sachindra S T Gamage, Thilanga N Pahattuge, Harshani Wijerathne, Katie Childers, Swarnagowri Vaidyanathan, Uditha S Athapattu, Lulu Zhang, Zheng Zhao, Mateusz L Hupert, Rolf M Muller and 12 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.8field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 7 institutions in 2 countries.

Sachindra S T GamageDepartment of Chemistry, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-7507-3226
Thilanga N PahattugeDepartment of Chemistry, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-3961-1664
Harshani WijerathneDepartment of Chemistry, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-9921-0731
Katie ChildersCenter of BioModular Multiscale Systems for Precision Medicine, The University of Kansas, Lawrence, KS 66045, USA.
Swarnagowri VaidyanathanCenter of BioModular Multiscale Systems for Precision Medicine, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0003-0397-5543
Uditha S AthapattuDepartment of Chemistry, The University of Kansas, Lawrence, KS 66045, USA.
Lulu ZhangCenter of BioModular Multiscale Systems for Precision Medicine, The University of Kansas, Lawrence, KS 66045, USA.
Zheng ZhaoDepartment of Chemistry, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0001-7068-1321
Mateusz L HupertBioFluidica Inc., San Diego, CA 92121, USA.
Rolf M MullerBioFluidica Inc., San Diego, CA 92121, USA.ORCID 0000-0002-1876-3976
Judy Muller-CohnBioFluidica Inc., San Diego, CA 92121, USA.
Janet DickersonBioFluidica Inc., San Diego, CA 92121, USA.ORCID 0000-0002-7481-8898
Dylan DufekBioFluidica Inc., San Diego, CA 92121, USA.ORCID 0000-0003-4599-7812
Brian V GeisbrechtDepartment of Biochemistry and Molecular Biophysics, Kansas State University, Manhattan, KS 66506, USA.ORCID 0000-0002-1775-0727
Harsh PathakDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS 66160, USA.ORCID 0000-0003-4034-0520
Ziyan PessettoSinochips Diagnostics, Olathe, KS 66061, USA.
Gregory N GanDepartment of Radiation Oncology, University of Kansas Medical Center, Kansas City, KS 66160, USA.ORCID 0000-0001-5090-0064
Junseo ChoiCenter of BioModular Multiscale Systems for Precision Medicine, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-3461-3820
Sunggook ParkCenter of BioModular Multiscale Systems for Precision Medicine, The University of Kansas, Lawrence, KS 66045, USA.
Andrew K GodwinCenter of BioModular Multiscale Systems for Precision Medicine, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-3987-9580
Malgorzata A WitekDepartment of Chemistry, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-2802-7235
Steven A SoperDepartment of Chemistry, The University of Kansas, Lawrence, KS 66045, USA.ORCID 0000-0002-8292-7058
University of Kansas · USBioFluidica (United States) · USLouisiana State University · USKansas State University · USSinochem Group (China) · CNThe University of Kansas Cancer Center · USUniversity of Kansas Medical Center · US

Funding

Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI ROY A. JENSEN · 2012 to 2026
$40.1M
Synthetic Chemical Biology CoreP20GM113117 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI OROZCO, ROBIN C. · 2016 to 2025
$23.9M
Understanding the mechanobiology of stem cells in a microengineered 3D cardiac tissue environment with cardiomyopathyP20GM103638 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI LUNTE, SUSAN M · 2012 to 2021
$22.1M
Using Integrated Omics to Identify Dysfunctional Genetic Mechanisms Influencing Schizophrenia and Sleep DisturbancesP20GM130423 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Kalyani Pyaram, Steven Allan Soper · 2019 to 2026
$21.5M
Single-Molecule Processing: Detection and Identification of Single DNAs, RNAs, and Proteins using Immobilized Nanoscale Enzymatic Reactors (INERs) and Nanoscale ElectrophoresisP41EB020594 · NIBIB · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Adam Roger Hall · 2015 to 2026
$15.2M
Synthetic Chemical Biology CoreP30GM145499 · NIGMS · UNIVERSITY OF KANSAS LAWRENCE · PI Susan M Lunte · 2022 to 2026
$6.9M
Structure/Function Studies of Enzyme Inhibitors and their Roles in Innate Immune EvasionR35GM140852 · NIGMS · KANSAS STATE UNIVERSITY · PI Brian V Geisbrecht · 2021 to 2026
$2.3M
NCI NIH HHS P30 CA168524NIBIB NIH HHS P41 EB020594NIGMS NIH HHS P20 GM103638NIGMS NIH HHS P20 GM113117NIGMS NIH HHS P20 GM130423NIGMS NIH HHS P30 GM145499NIGMS NIH HHS R35 GM140852
6 · The paper itself

Abstract

We report a microfluidic assay to select active severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral particles (VPs), which were defined as intact particles with an accessible angiotensin-converting enzyme 2 receptor binding domain (RBD) on the spike (S) protein, from clinical samples. Affinity selection of SARS-CoV-2 particles was carried out using injection molded microfluidic chips, which allow for high-scale production to accommodate large-scale screening. The microfluidic contained a surface-bound aptamer directed against the virus's S protein RBD to affinity select SARS-CoV-2 VPs. Following selection (~94% recovery), the VPs were released from the chip's surface using a blue light light-emitting diode (89% efficiency). Selected SARS-CoV-2 VP enumeration was carried out using reverse transcription quantitative polymerase chain reaction. The VP selection assay successfully identified healthy donors (clinical specificity = 100%) and 19 of 20 patients with coronavirus disease 2019 (COVID-19) (95% sensitivity). In 15 patients with COVID-19, the presence of active SARS-CoV-2 VPs was found. The chip can be reprogrammed for any VP or exosomes by simply changing the affinity agent.

Identifiers

PMID36170362
PMCPMC9519043
OpenAlexW4297502033

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.